论文部分内容阅读
目的 :比较司帕沙星片剂和氧氟沙星片剂治疗呼吸系统、泌尿系统和消化系统感染的疗效和安全性。 方法 :在上海市 7所医院进行多中心、随机、对照研究。司帕沙星组 (试验组 ) 110例 ,2 0 0 mg,1次 / d;氧氟沙星组 (对照组 ) 110例 ,2 0 0 mg,2～ 3次 / d。均口服 ,疗程均为 7～ 14d。 结果 :试验组和对照组的治疗有效率分别为 91.8%和 82 .7% ,痊愈率分别为 6 3.3%和 5 6 .4% ,细菌清除率分别为 94.3%和 88.7% ,均无统计学差异 (P>0 .0 5 )。分别比较试验组和对照组呼吸、泌尿和消化系统治疗的有效率和痊愈率 ,均无显著性差异 (P>0 .0 5 )。两组不良反应发生率分别为 2 .7%和 1.8% ,无统计学差异 (P>0 .0 5 )。结论 :司帕沙星片剂治疗临床感染性疾病的疗效和不良反应与氧氟沙星片剂相似 ,但用药 1次 / d,应用方便 ,值得推广。
Objective: To compare the efficacy and safety of sparfloxacin tablets and ofloxacin tablets in the treatment of respiratory, urinary and digestive infections. Methods: A multicenter, randomized, controlled study was performed in seven hospitals in Shanghai. The sparfloxacin group (experimental group) 110 cases, 200 mg, 1 time / d, ofloxacin group (control group) 110 cases, 200 mg, 2 to 3 times / d. All oral, treatment are 7 ~ 14d. Results: The effective rates of treatment and control were 91.8% and 82.7%, the cure rates were 6 3.3% and 56.4% respectively, and the bacterial clearance rates were 94.3% and 88.7% respectively, with no statistical significance Differences (P> 0.05). There was no significant difference between the effective rate and the cure rate of respiratory, urinary and digestive system in the experimental group and the control group (P> 0.05). The incidence of adverse reactions in both groups were 2.7% and 1.8%, respectively, with no significant difference (P> 0.05). Conclusion: The efficacy and side effects of sparfloxacin tablets in the treatment of clinical infectious diseases are similar to those of ofloxacin tablets. However, once a day / d, the application is convenient and should be popularized.